Nuvectis Pharma (NVCT) CEO Ron Bentsur buys $250,000 in shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Nuvectis Pharma Chairman and CEO Ron Bentsur bought 12,500 shares of common stock at $20.00 per share in an open-market purchase tied to a public offering announced on June 29, 2026, for a total of $250,000.
After this transaction, he directly owns 3,688,424 shares of Nuvectis Pharma common stock, including shares of restricted common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 12,500 shares ($250,000)
Net Buy
1 txn
Insider
BENTSUR RON
Role
Chairman & CEO
Bought
12,500 shs ($250K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 12,500 | $20.00 | $250K |
Holdings After Transaction:
Common Stock — 3,688,424 shares (Direct, null)
Footnotes (1)
- Mr. Bentsur purchased 12,500 shares for $250,000 in the public offering announced on June 29, 2026. Includes shares of restricted common stock.
Key Figures
Shares bought: 12,500 shares
Purchase price: $20.00 per share
Transaction value: $250,000
+2 more
5 metrics
Shares bought
12,500 shares
Open-market purchase on June 30, 2026
Purchase price
$20.00 per share
Common stock transaction
Transaction value
$250,000
12,500 shares in public offering
Shares after transaction
3,688,424 shares
Total direct holdings following purchase
Net buy shares
12,500 shares
Net buy direction in transaction summary
Key Terms
open-market purchase, restricted common stock, public offering, Form 4
4 terms
open-market purchase financial
"transaction_action: open-market purchase"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
restricted common stock financial
"Includes shares of restricted common stock."
Restricted common stock is company shares that carry limits on selling or transferring for a set period or until certain conditions are met, like time-based vesting or regulatory clearance. Think of them as shares in a locked box that gradually open; they can become freely tradable later but initially reduce the number of shares available on the market. Investors watch restricted stock because its eventual release can change a company’s share supply, affect stock price, and influence control and dilution.
public offering financial
"shares for $250,000 in the public offering announced on June 29, 2026"
A public offering is when a company sells shares to the general public through the stock market, either by issuing new shares to raise cash or by letting existing owners sell their stakes. Think of it like a business opening its doors to many new owners at once: it can bring in money for growth but also increases the number of shares available, which can change the stock price and dilute existing ownership — key factors investors watch closely.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
What insider transaction did Nuvectis Pharma (NVCT) report on this Form 4?
Nuvectis Pharma reported that Chairman and CEO Ron Bentsur bought 12,500 shares of common stock at $20.00 per share, a $250,000 open-market purchase connected to a public offering announced June 29, 2026.
What type of security did the Nuvectis Pharma (NVCT) insider acquire?
The filing shows Ron Bentsur acquired Nuvectis Pharma common stock. It also states that his post-transaction holdings include shares of restricted common stock within the total 3,688,424 shares.